TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Enhancing Tobacco Use Treatment for African American Light Smokers
Brief Summary: RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking.

PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.


Options:
A: Inclusion Criteria:

1. 18 years of age and older;
2. diagnosis of HIV;
3. self-reported smoking on a daily basis;
4. provide informed written consent

Exclusion Criteria:

1. persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam)
2. unable to understand spoken English
3. age less than 18 years.
4. pregnant women
B: Inclusion Criteria:

* Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months

Exclusion Criteria:

* Insufficient level of motivation
* Another participant in the household
* Patients with current psychotic disorder or major depressive disorder

The investigator will evaluate whether there are other reasons why a patient may not participate.
C: DISEASE CHARACTERISTICS:

* African American who has smoked ≤ 10 cigarettes per day for ≥ 2 years AND has smoked for ≥ 25 days within the past month

  * Not a heavy smoker
  * No other forms of tobacco within the past 30 days
* Must be interested in stopping smoking
* No other smoker in the household enrolled in this study

PATIENT CHARACTERISTICS:

* Has a home address and a functioning telephone number
* Not planning to move from the Kansas City metro area within the next 12 months
* Not pregnant or nursing
* Negative pregnancy test
* No alcohol or substance abuse within the past year
* Not currently drinking ≥ 14 alcoholic drinks per week
* No binge drinking (5 or more drinks on one occasion) on at least two occasions within the past month
* No history of seizures or head trauma
* No history of bulimia or anorexia nervosa
* No myocardial infarction within the past 30 days
* No reported use of opiates, cocaine, or stimulants
* No diabetes requiring oral hypoglycemics or insulin

PRIOR CONCURRENT THERAPY:

* More than 30 days since prior nicotine replacement therapy, fluoxetine, clonidine, buspirone, or doxepin
* No other concurrent medication that contains bupropion hydrochloride
* No concurrent psychoactive medications
D: Inclusion Criteria:

* Subjects must have smoked on average of at least ten cigarettes per day during the past year
* Subjects must have no period of abstinence greater than three months in the past year

Exclusion Criteria:

* Subjects with any history of clinically significant cardiovascular disease
* Uncontrolled hypertension

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Femoral Arterial Access With Ultrasound Trial
Brief Summary: This study is designed to evaluate the routine use of vascular ultrasound as an aid for proper placement of a femoral arterial sheath during cardiac catheterization and peripheral arterial angiography.


Options:
A: Inclusion Criteria:

* All patients undergoing coronary catheterisation through radial artery

Exclusion Criteria:

* Presence of haemodynamic instability
* Planned IABP insertion
* Previous trauma or surgical intervention in the instrumented arm
* Impossibility to obtain informed consent
B: Inclusion Criteria:

* Patients requiring arterial line placement.

Exclusion Criteria:

* Adults Unable to Consent
* Members of Vulnerable Populations
C: Inclusion Criteria:

* Adults age 18 and over
* Patients undergoing left heart catheterization or peripheral arterial angiography from the retrograde femoral approach
* Willingness and ability to sign consent form
* Scheduled to have procedure performed by operator trained in the ultrasound technique

Exclusion Criteria:

* Access from a site other than the common femoral artery
* Nonpalpable femoral pulses
* Creatinine \> 3.0 mg/dl, unless already on dialysis
* Prisoners
* Pregnant women
* Unable or refusal to sign consent form
* Patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction or unstable acute coronary syndrome
* Equipment unavailable
D: Inclusion Criteria:

* All surgical intensive care unit patients at Yale New Haven Hospital in whom the indication for arterial catheterization has been established by the attending physician will be eligible for consented randomization to either the "Palpation" or the "Ultrasound" group.

Exclusion Criteria:

* The patient or his/her surrogate declines to participate or the patient lacks a radial artery into which a catheter can be place.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Femoral Arterial Access With Ultrasound Trial
Brief Summary: This study is designed to evaluate the routine use of vascular ultrasound as an aid for proper placement of a femoral arterial sheath during cardiac catheterization and peripheral arterial angiography.


Options:
A: Inclusion Criteria:

* Adults age 18 and over
* Patients undergoing left heart catheterization or peripheral arterial angiography from the retrograde femoral approach
* Willingness and ability to sign consent form
* Scheduled to have procedure performed by operator trained in the ultrasound technique

Exclusion Criteria:

* Access from a site other than the common femoral artery
* Nonpalpable femoral pulses
* Creatinine \> 3.0 mg/dl, unless already on dialysis
* Prisoners
* Pregnant women
* Unable or refusal to sign consent form
* Patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction or unstable acute coronary syndrome
* Equipment unavailable
B: Inclusion Criteria:

* Patients undergoing cardiac surgery
* Age 19 or older
* Provided written informed consent

Exclusion Criteria:

* Suspected inability to comply with study procedures, including language difficulties or medical history and/or concomitant disease, as judged by the investigator
* Previous surgery at the site of proposed radial artery catheterization
* Any vascular condition that may preclude eligibility for radial artery line insertion as judged by the investigator
* Patients with ventricular assist devices
* Previous inclusion in this study
C: Inclusion Criteria:

* all patients with clear indication to radial artery catheterization like hemodynamic instability or the need of frequent arterial samples

Exclusion Criteria:

* refusal, Peripheral arterial diseases
D: Inclusion Criteria:

* Adult patients presenting for cardiac or peripheral catheterization with planned radial approach.
* Barbeau's or Allen's test indicating at least some degree of collateral circulation in palmar vessels
* Functional ultrasound equipment with ultrasound trained attending operator

Exclusion Criteria:

* Inability to provide informed consent
* Femoral access
* Emergency procedure (Shock, STEMI)
* End-stage renal disease on hemodialysis
* Previous ipsilateral puncture within 1 week

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A New Clinical Pathway for Patients With Fractured Neck of Femur - The Orthopedics Operate, the Geriatricians Manage the Medical Work-up
Brief Summary: The intention is to evaluate the effectiveness of a multi-factorial medical treatment of patients with hip fractures in a specially designed unit for elderly hip fracture patients (orthogeriatric unit) as compared to traditional care in an orthopedic unit.


Options:
A: Inclusion Criteria:

* age \>70 years
* living in nearby municipalities
* able to walk 10 m before fracture
* medial, pertrochanteric and subtrochanteric hip-fractures

Exclusion Criteria:

* nursing home residents
* expected to die within 3 months
* pathological fractures
B: Inclusion Criteria:

* presenting with acute hip fracture
* aged 65 or more
* able to speak and understand Swedish
* community dwelling pre-fracture
* independent walking indoors with or without walking aid and in personal care with exception of bathing/showering.

Exclusion Criteria:

* severe drug or alcohol abuse
* mental illness
* documented cognitive impairment ≤ 8 according to the Short Portable Mental Status Questionnaire (SPMSQ)
C: Inclusion Criteria:

* Patients who are 65 years of age and older, and who have been admitted for a hip fracture to the Fracture Service at New York Presbyterian Hospital.

Exclusion Criteria:

* Patients who are unable to give informed consent on the 4th or 5th day after surgery.
* Patients whose hip fracture is due to underlying disease, secondary to malignancy (cancer).
* Patients who do not speak English.
* Patients for whom exercise is contraindicated or whose physicians believe that exercise is contraindicated.
* Patients who do not have access to a telephone or cannot be reached by telephone.
* Patients and physicians who refuse to participate or who intend to relocate upon discharge.
D: Inclusion Criteria:

* Patients admitted to St Luke's Hospital for the purpose of rehabilitation after a new hip fracture.

Exclusion Criteria:

* Patients were excluded if any of the following criteria were present: (i) Pre-morbid non-ambulatory status, (ii) nursing home residents, (iii) palliative care patients, and (iv) patients previously enlisted for the trial.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705
Brief Summary: The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.


Options:
A: Inclusion Criteria:

* Patient is male or female and at least 18 years of age
* Female patients must be of either:

  * Non-childbearing potential, post-menopausal
  * Childbearing potential, provided there are negative serum and urine pregnancy test results prior to study treatment, to rule out pregnancy

Exclusion Criteria:

* Cosmetic or therapeutic procedures within 2 weeks and 2cm of the selected treatment area
* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks
* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area
B: Inclusion Criteria:

* Must be male or female and at least 18 years of age.
* Female patients must be of:
* Non-childbearing potential;
* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.
* 4 to 8 AK lesions on non-head locations.

Exclusion Criteria:

* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.
* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.
* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area
C: Inclusion Criteria:

* Are willing and able to give informed consent;
* Have successfully completed one of the following studies: GW01-0702, GW01- 0703, GW01-0704, or GW01-0705 and have been determined to be completely clear of AK lesions at the EOS visit in the designated treatment area from the previous study
* Are willing to participate in the study as an outpatient, make visits to the study center for follow-up evaluation, and agree to comply with all study requirements.

Exclusion Criteria:

* None. All subjects who meet the inclusion criteria above may participate.
D: Inclusion Criteria:

* Must be male or female and at least 18 years of age.
* Female patients must be of:
* Non-childbearing potential;
* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.
* 4 to 8 AK lesions on non-head locations.

Exclusion Criteria:

* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.
* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.
* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Placebo-controlled, Randomised, Double-blind Study to Investigate the Efficacy and Safety of Low Dose Hydrocortisone to Prevent the Development of Septic Shock in Patients With Severe Sepsis
Brief Summary: Severe sepsis is a disease with a high mortality. Development of shock is a most serious complication and increases the risk of death considerably. Application of low dose hydrocortisone is currently recommended only in patients after severe septic shock has been established. Hydrocortisone therapy has a hemodynamic stabilizing effect and may reverse shock, however, the preventive application has not been investigated in a larger study. The study investigates whether low dose hydrocortisone prevents the development of shock in patients with severe sepsis. It is postulated that shock prevention may also affect morbidity and mortality.


Options:
A: Inclusion Criteria:

* Severe sepsis according to ACCP/CCM criteria
* Onset of severe sepsis \< 48 hours
* Informed consent
* Effective contraception in fertile women

Exclusion Criteria:

* Septic shock
* Known hypersensitivity to hydrocortisone and additives
* Glucocorticoid history which warrants continuation of glucocorticoid administration
* Other indication for systemic glucocorticoid therapy
* DNR-order
* Moribund patient
* Pregnancy
* Breast feeding women
* Age \< 18 years
* Other interventional study
* Relationship to investigator
B: Inclusion Criteria:

* males and females,
* between 18 and 75 year old
* who present a burned surface more than 30% of the body surface
* who need catecholamine infusion
* between J0 and J3 after the injury.

Exclusion Criteria:

* pregnancy,
* trauma,
* sepsis,
* cardiac insufficiency,
* AIDS,
* etomidate administration
C: Inclusion Criteria:

* Trauma brain injury (Glasgow score below 8 and lesion on scanner)
* Informed consent
* Time to inclusion inferior to 24 hours

Exclusion Criteria:

* Tetraplegia
* Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (excluding inhaled steroids). Topical steroids are not exclusions
* Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study
* Antibiotherapy for active sepsis at the time of inclusion
D: Inclusion Criteria:

* Age superior of 15 years
* Hospitalization in reanimation for polytraumatism (lesion of two organs with a vital risk)
* SISS score more than 15
* Intubation for more than 48 hours.
* Agreement of a family member
* Patient with insurance

Exclusion Criteria:

* History of corticothérapies within 6 months
* History of adrenocortical insufficiency.
* Treatment by immunosuppressor
* Immunodeficiency.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.
Brief Summary: This prospective randomized double-blind placebo vs control study aims at verifying the efficacy of tranexamic acid administration in reducing perioperative bleeding in patients undergoing open radical prostatectomy. Two recent meta-analysis confirmed that tranexamic acid administration does not increase mortality, myocardial infarction, deep venous thrombosis, pulmonary embolism, stroke and renal failure.

200 patients undergoing open radical prostatectomy will be enrolled. Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.

Patients belonging to the control group will receive the same volume of saline infusions.


Options:
A: Inclusion Criteria:

1. Patients aged \> 18 years old
2. Patients with renal stone or stones of 10-30 mm in maximal diameter measured in computed tomography scan.
3. Decision of the patient to receive surgical treatment
4. Ability to understand and provide a written informed consent to participate in the study.

Exclusion Criteria:

1. Solitary kidney (functional or organic)
2. Ureteral stone in the same system causing obstruction
3. Malignant tumor in the treated kidney
4. Stone in diverticulum
5. Diabetes or coronary heart disease.
6. History of surgery in the treated kidney
7. Recent intake of drugs that affect renal function or intravenous contrast agent
8. Concomitant urinary infection
9. Congenital anomalies of the urinary tract
10. Patients of whom incomplete clinical data or incomplete samples are available
B: Inclusion Criteria:

* adult patients
* with acute significant upper or lower gastrointestinal bleeding
* where the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents in the patient

Exclusion Criteria:

* The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular patient with upper or lower gastrointestinal bleeding.
* There are no other exclusions.
C: Inclusion Criteria:

* The patients who have 2 to 4 cm kidney stones
* ASA score within 1 to 3

Exclusion Criteria:

* Previous surgical treatment including SWL
* Congenital abnormalities
D: Inclusion Criteria:

* Adult patients
* Patients undergoing open radical prostatectomy

Exclusion Criteria:

* Age \< 18 years
* Patients with drug eluting stent with a double antiplatelet therapy
* Atrial fibrillation
* Thrombophilic diathesis
* Allergy to tranexamic acid

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Inclusion Criteria:

* Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit.
* mild to moderate COPD confirmed by spirometry
* Subjects must have a clinical diagnosis of COPD.

Exclusion Criteria:

* Subjects who have made a serious attempt to quit smoking in the past 3 months.
* Subjects who have been previously randomized in a study that has included varenicline.
B: Inclusion Criteria:

* Adult daily smokers in the county of Västmanland

Exclusion Criteria:

* Reading difficulties
* Not fluent in the Swedish language
C: Inclusion Criteria:

* Smoker of at least 10 cigarettes per day on average over the past 12 months
* Inpatient with an anticipation admission of at least one day
* Willingness to quit smoking
* Aged between 20 and 75 years
* A plan of discharge to go home
* Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease

Exclusion Criteria:

* Subject preference to use an alternative pharmacotherapy for smoking cessation
* Respiratory patient being considered for home oxygen
* Pregnancy
* Breast feeding
* Acute or pre-existing severe psychiatric illnesses
* Past history of psychosis or suicidal ideation
* Renal impairment with creatinine clearance \<30ml/min
D: Inclusion Criteria:

* Age ≥18 years Smoking ≥ 10 cigarettes per day Patients with disease conditions known to be related to smoking: e.g.coronary heart diseases, COPD, lower extremity arterial disease, etc

Exclusion Criteria:

* Smokers whose follow-up during the duration of the study, in a predictable way, cannot be assured.
* smokers having been treated by bupropion ( Zyban) during two months preceding the inclusion
* persons under TSN, neuroleptic, substitute treatments in OPINOIDES, under anticoagulants-non-equilibrating,
* encircled woman
* breast-feeding woman
* Contraindication usual of the TSN

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Inclusion Criteria:

* Born on 1979.
* Living in Vaasa, Pietarsaari, Kokkola or Seinäjoki at school age.

Exclusion Criteria:

* Other year of birth.
B: Inclusion Criteria:

* Clinics are included if they are located within the NYC metropolitan area and employ at least three FTE dentists.
* Providers are included if they practice full-time or part-time at one of the study clinics
* Patients are included if they are 18 years or older, active smokers defined as those who report smoking cigarettes some days, most days, or every day and have smoked in the past 7 days, have an appointment with a dentist or hygienist, NYS resident, speak English, Spanish, Chinese or Russian, and are able to comply with study procedures in the opinion of the principal investigator.

Exclusion Criteria:

* Clinic locations are excluded if the number of unique adult patient visits per week averages less than 100, if the dental director reports that the clinic assists more than 60% of patients with tobacco cessation and if the clinics policies would prohibit the clinic from accepting pay-for-performance funds if randomized to that arm. All sites with less than 3 dental providers will also be excluded.
* Providers are excluded if they do not speak English.
* Patients are excluded if they do not speak English, Spanish, Chinese or Russian, and if they have already completed the patient exit interview during the same intervention phase.
C: Inclusion Criteria:

* Adult daily smokers in the county of Västmanland

Exclusion Criteria:

* Reading difficulties
* Not fluent in the Swedish language
D: Inclusion Criteria:

* general dental practices that have internet access
* Periodontal practices that have internet access
* patients of participating dental or periodontal practices

Exclusion Criteria:

* patients who were 18 years of age and younger

Answer: C